If you work for a company that is giving employees an opportunity to have a conversation with an expert concerning COVID vaccination, say their PharmD, what might you ask?
Our Sept 11 dispatch suggested several questions: Can you delay the requirement pending availability of the only FDA-approved product, labeled Comirnaty, or better yet, completion of studies on myocarditis to be completed in 2027?
In addition, consider the data from Israel showing twice as many COVID deaths in 2021, with one of the highest vaccination rates in the world, compared with 2020, before the vaccines were available.
Questions for the company’s expert:
- How do you explain the 100-percent increase in cases and deaths in almost-fully-vaccinated Israel?
- If there is to be a testing requirement, will it apply to all? President Biden said: “We need to protect the vaccinated from the unvaccinated.” How will we know whether they have been protected without testing them?
- There have been reports by unvaccinated persons, especially of menstrual irregularities, after contact with vaccinated persons. Will the company collect reports, offer testing as for coagulation abnormalities, or institute any precautions?
- Can the company expert provide references to male and female fertility studies in several species of animals? What about pathologic examination of the placenta in women who had a miscarriage post vaccination (1,757 reports to the Vaccine Adverse Event Reporting System, VAERS, as of Sept 9)?
- Will the company allow alternate methods of COVID prophylaxis such as iodinated mouthwash and nasal spray, iota-carrageenan, ivermectin, hydroxychloroquine, or other measures? Results of studies for pre-exposure and post-exposure prophylaxis are compiled at c19study.com.